<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Institute of Ophthalmology</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/81ECE0B1-688A-4295-AE7F-2BFC9820E832"><gtr:id>81ECE0B1-688A-4295-AE7F-2BFC9820E832</gtr:id><gtr:firstName>Sidath</gtr:firstName><gtr:otherNames>Elaboda</gtr:otherNames><gtr:surname>Liyanage</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FK003003%2F1"><gtr:id>1F12D264-2A9D-4951-92A1-494E788AC95D</gtr:id><gtr:title>Hypoxia-inducible factors in age-related macular degeneration</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>MR/K003003/1</gtr:grantReference><gtr:abstractText>Age-related macular degeneration, also known as AMD, is the commonest cause of sight loss in the Western world. More than 500,000 people are affected in the United Kingdom. This serious condition affects the macula, the part of the retina which deals with seeing central vision, colours and fine detail. AMD is responsible for approximately 250,000 people being registered as partially sighted.

This condition usually affects people from the age of 60, causing a range of symptoms, including distorted vision, blurred vision and smudges or gaps in their vision. There are two main types of AMD, known as 'dry' and 'wet'. In dry AMD, the cells of the macula gradually die, usually resulting in a slow deterioration in vision over several years. There is no effective treatment for this.

In wet AMD, abnormal blood vessels grow behind the macula and can bleed or leak, causing a rapid loss of central vision. We know that in wet AMD, the eye produces a molecule known as 'vascular endothelial growth factor' or VEGF which encourages the growth of these blood vessels. Treatments developed to counteract this molecule can improve outcome but are incompletely effective, and depend on repeated injections into the eye that risk serious side effects.

We know that VEGF is important in the development of the eye and maintaining healthy blood vessels. We do not know exactly what causes AMD and why abnormal amounts of VEGF are produced. This research project aims to investigate these questions. This is important because in order to try to provide more effective treatments or even prevent this disease, we need to fully understand the processes involved.

The production of VEGF and other molecules in the body are controlled by switching various genes on and off. One of these genes is 'hypoxia-inducible factor' or HIF. By using various methods, we can switch the HIF gene on and off and analyse its effect on the production of VEGF and any abnormal blood vessels. These experimental models can help us to understand how HIF contributes to formation of abnormal blood vessels in wet AMD. This will enable us to develop more effective treatments for this condition.

This work will be carried out by researchers at the Institute of Ophthalmology in London, where similar research into gene therapy has resulted in potential treatments for other debilitating eye conditions.</gtr:abstractText><gtr:technicalSummary>In this fellowship I will investigate the hypothesis that hypoxia-inducible factor (HIF) activation in myeloid cells is responsible for neovascular age-related macular degeneration. The aim is to define the molecular and cellular processes responsible for choroidal neovascularisation (CNV) by investigating the role of HIFs in myeloid cells during experimental CNV.

I will investigate the specific roles of HIF1a and HIF2a in myeloid cells in normal retina and during experimental CNV by manipulating HIF pathways using highly targeted transgenic approaches. I will use transgenic mice that express cre-recombinase under the control of the myeloid specific promoter lysM. This mouse line facilitates the efficient cre-mediated deletion of HIF-related target genes in myeloid cells and is therefore a suitable tool to investigate the role of circulation-derived and resident myeloid cells in the development of CNV using immunohistochemistry, flow cytometry and in vivo angiography. 

The objectives are:
1) To determine the distribution of myeloid cells in the normal retina and in experimental CNV
2) To characterize these cells by immunophenotyping in vitro and in vivo 
3) To determine the impact of HIF activation on the extent of CNV
4) To determine the role of HIF activation in recruitment of myeloid cell populations to CNV

By defining the role of HIF in myeloid cells in the development of experimental CNV I aim to identify new opportunities to improve the efficacy of therapeutic intervention.</gtr:technicalSummary><gtr:potentialImpactText>Age-related macular degeneration (AMD) is the commonest cause of blindness in the developed world. Current treatment modalities for neovascular AMD aim to inhibit the effects of vascular endothelial growth factor (VEGF). The hypoxia-inducible factor (HIF) pathway promotes the transcriptional activity of a wide range of genes, including VEGF. By defining the role of HIFa isoforms in myeloid cells in the development of experimental choroidal neovascularisation, I hope to identify new opportunities to improve the efficacy of therapeutic intervention in neovascular AMD.

Due to the prevalence of AMD and its impact on the lives of those affected, there is considerable interest within the research community (both nationally and internationally) aimed at therapeutic intervention. Findings will immediately complement existing research, benefiting this community and the commercial private sector.

Having developed gene and cell therapy approaches for a wide range of ocular disorders and demonstrated proof of principle in clinical application, Professors Bainbridge and Ali have the relevant expertise and infrastructural resources to translate relevant findings into new interventions for the benefit of patients. It is anticipated that development of a new molecular intervention from preclinical proof of concept to clinical application will take approximately 5 years.

In the long term, if a clinical application is developed, patients will benefit by having a potentially more effective treatment. This would positively affect quality of life while decreasing the morbidity associated with this condition. Development of new modalities may benefit policy-makers, governments and government agencies by providing a potentially more cost-effective approach to the treatment of this condition. This is important when considering the ageing demographic and its impact on healthcare.</gtr:potentialImpactText><gtr:fund><gtr:end>2015-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>249897</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>604BA0A2-993D-40F5-AD9F-F02A969020A5</gtr:id><gtr:title>Cd59a deficiency in mice leads to preferential innate immune activation in the retinal pigment epithelium-choroid with age.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d205b6b18b88378c1cf23db4a1a8d56c"><gtr:id>d205b6b18b88378c1cf23db4a1a8d56c</gtr:id><gtr:otherNames>Herrmann P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>56dffb66b63b48.83349835</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>553259FF-43AA-4A04-8867-4E5DD0FF8E39</gtr:id><gtr:title>Hypoxia inducible factors are dispensable for myeloid cell migration into the inflamed mouse eye.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb2cbd8d835567f2f7b01bc6c304e3c9"><gtr:id>eb2cbd8d835567f2f7b01bc6c304e3c9</gtr:id><gtr:otherNames>Gardner PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>58c728ad125b49.23259539</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>95375382-5940-4DAA-B15A-2421B98DEF2A</gtr:id><gtr:title>Multimodal analysis of ocular inflammation using the endotoxin-induced uveitis mouse model.</gtr:title><gtr:parentPublicationTitle>Disease models &amp; mechanisms</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/223de347f407a52493f71e53c17bc658"><gtr:id>223de347f407a52493f71e53c17bc658</gtr:id><gtr:otherNames>Chu CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1754-8403</gtr:issn><gtr:outcomeId>56dffcc8a6b8f2.29752409</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D5958371-868F-41BC-9C97-488883A5EEF4</gtr:id><gtr:title>Assessment and in vivo scoring of murine experimental autoimmune uveoretinitis using optical coherence tomography.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/223de347f407a52493f71e53c17bc658"><gtr:id>223de347f407a52493f71e53c17bc658</gtr:id><gtr:otherNames>Chu CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_24618_28_23690973</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>503C584F-CAD0-4FC6-A7DC-47F65C4BD248</gtr:id><gtr:title>Myeloid-Derived Vascular Endothelial Growth Factor and Hypoxia-Inducible Factor Are Dispensable for Ocular Neovascularization--Brief Report.</gtr:title><gtr:parentPublicationTitle>Arteriosclerosis, thrombosis, and vascular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2e451f25e48390bcafc37ac57e554706"><gtr:id>2e451f25e48390bcafc37ac57e554706</gtr:id><gtr:otherNames>Liyanage SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1079-5642</gtr:issn><gtr:outcomeId>56dffb6661fdf0.74406831</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6BA6A4D2-93FB-487B-B1AF-BF76E45332CD</gtr:id><gtr:title>A simple method for in vivo labelling of infiltrating leukocytes in the mouse retina using indocyanine green dye.</gtr:title><gtr:parentPublicationTitle>Disease models &amp; mechanisms</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9e30f9d3e62a87480ccf0bddd5156f03"><gtr:id>9e30f9d3e62a87480ccf0bddd5156f03</gtr:id><gtr:otherNames>Sim DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1754-8403</gtr:issn><gtr:outcomeId>56dffb668a0118.90543616</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D5763E15-F4DF-4BF3-91A2-5992300CB909</gtr:id><gtr:title>VEGF165-induced vascular permeability requires NRP1 for ABL-mediated SRC family kinase activation.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86e60af15e937832c33be867a2917416"><gtr:id>86e60af15e937832c33be867a2917416</gtr:id><gtr:otherNames>Fantin A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>5aa84f06ccbc02.86474003</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9754DACC-3340-4E1B-A372-12D7BF9EE0DA</gtr:id><gtr:title>Flow cytometric analysis of inflammatory and resident myeloid populations in mouse ocular inflammatory models.</gtr:title><gtr:parentPublicationTitle>Experimental eye research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2e451f25e48390bcafc37ac57e554706"><gtr:id>2e451f25e48390bcafc37ac57e554706</gtr:id><gtr:otherNames>Liyanage SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0014-4835</gtr:issn><gtr:outcomeId>58c728acba3032.47380557</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E5439DD1-A1E2-4292-BFEB-E531DD8EFAE5</gtr:id><gtr:title>IL-4 regulates specific Arg-1(+) macrophage sFlt-1-mediated inhibition of angiogenesis.</gtr:title><gtr:parentPublicationTitle>The American journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/106fa455eb9a9c983a64d6aa5ce6d27f"><gtr:id>106fa455eb9a9c983a64d6aa5ce6d27f</gtr:id><gtr:otherNames>Wu WK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0002-9440</gtr:issn><gtr:outcomeId>56dffb66e666b9.16685237</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/K003003/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>A9061818-9B1E-495A-9617-7C77200827C2</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Eye</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>